Skip to main content

previous disabled Page of 4
and
  1. Article

    Open Access

    Legacy of the discovery of the T-cell receptor: 40 years of sha** basic immunology and translational work to develop novel therapies

    Yufang Shi, Andreas Strasser, Douglas R. Green in Cellular & Molecular Immunology (2024)

  2. Article

    Open Access

    Autoantibodies against chemokines post-SARS-CoV-2 infection correlate with disease course

    Infection with severe acute respiratory syndrome coronavirus 2 associates with diverse symptoms, which can persist for months. While antiviral antibodies are protective, those targeting interferons and other i...

    Jonathan Muri, Valentina Cecchinato, Andrea Cavalli in Nature Immunology (2023)

  3. Article

    Reply to: Hultström et al., Genetic determinants of mannose-binding lectin activity predispose to thromboembolic complications in critical COVID-19. Mannose-binding lectin genetics in COVID-19

    Rosanna Asselta, Elvezia Maria Paraboschi, Matteo Stravalaci in Nature Immunology (2022)

  4. Article

    Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules

    The humoral arm of innate immunity includes diverse molecules with antibody-like functions, some of which serve as disease severity biomarkers in coronavirus disease 2019 (COVID-19). The present study was desi...

    Matteo Stravalaci, Isabel Pagani, Elvezia Maria Paraboschi in Nature Immunology (2022)

  5. No Access

    Article

    Tumor-associated myeloid cells: diversity and therapeutic targeting

    Myeloid cells in tumor tissues constitute a dynamic immune population characterized by a non-uniform phenotype and diverse functional activities. Both tumor-associated macrophages (TAMs), which are more abunda...

    Alberto Mantovani, Federica Marchesi, Sebastien Jaillon in Cellular & Molecular Immunology (2021)

  6. Article

    Author Correction: A guiding map for inflammation

    A Correction to this paper has been published: https://doi.org/10.1038/ni.3790

    Mihai G. Netea, Frances Balkwill, Michel Chonchol, Fabio Cominelli in Nature Immunology (2021)

  7. No Access

    Chapter

    Adoptive T-Cell Therapy: Optimizing Chemokine Receptor-Mediated Homing of T-Cells in Cancer Immunotherapy

    Immunotherapy based on adoptive T-cell transfer provides a promising form of cancer therapy, but often fails to induce long-lasting responses in the great majority of patients. During the past few decades, sev...

    Imran Siddiqui, Debora Vignali, Marinos Kallikourdis in Cancer Immunology (2021)

  8. Article

    Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19

    Long pentraxin 3 (PTX3) is an essential component of humoral innate immunity, involved in resistance to selected pathogens and in the regulation of inflammation13. The present study was designed to assess the pr...

    Enrico Brunetta, Marco Folci, Barbara Bottazzi, Maria De Santis in Nature Immunology (2021)

  9. No Access

    Article

    The other side of the innate immune system: humoral arms favoring cancer

    Cancer cells take advantage of NETosis to escape host immune surveillance and mediate metastasis. The pharmacological targeting of NETosis may prove beneficial in maximizing the response to cancer immunotherapy.

    Maria De Santis, Alberto Mantovani, Carlo Selmi in Cellular & Molecular Immunology (2020)

  10. No Access

    Chapter

    Tumor-Associated Myeloid Cells in Cancer Progression

    The tumor microenvironment plays a pivotal role in orchestrating tumor initiation, progression, and spreading, as well as response to therapy. Myeloid immune cells infiltrating tumors are integral component of...

    Tamara Gulic, Rita Silva-Gomes, Sadaf Davoudian, Marina Sironi in Cancer Immunology (2020)

  11. No Access

    Article

    ‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development

    Therapeutic innovations of potentially great clinical impact should embrace the overarching values of research accountability, data transparency and validation through the scientific peer-review process.

    Dimitrios C. Mastellos, Anna M. Blom, E. Sander Connolly in Nature Immunology (2019)

  12. Article

    Author Correction: ‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development

    An amendment to this paper has been published and can be accessed via a link at the top of the paper.

    Dimitrios C. Mastellos, Anna M. Blom, E. Sander Connolly in Nature Immunology (2019)

  13. Article

    Open Access

    The great debate at “Immunotherapy Bridge 2018”, Naples, November 29th, 2018

    As part of the 2018 Immunotherapy Bridge congress (November 28–29, Naples, Italy), the Great Debate session featured counterpoint views from leading experts on four topical clinical issues in immunotherapy tod...

    Paolo A. Ascierto, Lisa H. Butterfield in Journal for ImmunoTherapy of Cancer (2019)

  14. No Access

    Article

    The macrophage tetraspan MS4A4A enhances dectin-1-dependent NK cell–mediated resistance to metastasis

    The plasma membrane tetraspan molecule MS4A4A is selectively expressed by macrophage-lineage cells, but its function is unknown. Here we report that MS4A4A was restricted to murine and human mononuclear phagoc...

    Irene Mattiola, Federica Tomay, Maria De Pizzol, Rita Silva-Gomes in Nature Immunology (2019)

  15. No Access

    Chapter

    Microenvironment and Immunology of the Human Pleural Malignant Mesothelioma

    Human malignant pleural mesothelioma (MPM) is strongly related to pre-existing and long-lasting conditions of chronic inflammation and tissue injury, caused by the inhalation of airborne asbestos fibers. The l...

    Elisabeth Digifico, Cristina Belgiovine, Alberto Mantovani, Paola Allavena in Mesothelioma (2019)

  16. Article

    Alessandro Moretta 1953–2018

    Lorenzo Moretta, Alberto Mantovani in Nature Immunology (2018)

  17. No Access

    Article

    Complement in cancer: untangling an intricate relationship

  18. Complement potentiates various forms of cancer therapy, including antibody-mediated cytotoxicity, vaccines and radiotherapy.

  19. ...
  20. Edimara S. Reis, Dimitrios C. Mastellos, Daniel Ricklin in Nature Reviews Immunology (2018)

  21. No Access

    Article

    A guiding map for inflammation

    Netea and colleagues provide a general guide to the cellular and humoral contributors to inflammation as well as the pathways that characterize inflammation in specific organs and tissues.

    Mihai G Netea, Frances Balkwill, Michel Chonchol, Fabio Cominelli in Nature Immunology (2017)

  22. No Access

    Article

    Atypical matters in myeloid differentiation

    Chemokines are important components of the hematopoietic niche. The atypical chemokine receptor 1 (ACKR1), expressed on erythrocyte precursors, regulates myeloid differentiation.

    Massimo Locati, Alberto Mantovani, Raffaella Bonecchi in Nature Immunology (2017)

  23. No Access

    Article

    Reflections on immunological nomenclature: in praise of imperfection

    Alberto Mantovani in Nature Immunology (2016)

previous disabled Page of 4